Global Marginal Zone Lymphoma Treatment Market, By Treatment Type (Immunotherapy, Radiation Therapy, Chemotherapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Marginal Zone Lymphoma Treatment Market Analysis and Size
The global marginal zone lymphoma treatment market. is expected to witness significant growth during the forecast period. Marginal zone lymphoma is considered the third most common sub-type of non-Hodgkin’s lymphoma (NHL) and is highly indolent. As per the Lymphoma Research Foundation, marginal zone lymphomas mostly account for around 8% of all non-Hodgkin’s lymphoma cases. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global marginal zone lymphoma treatment market. in the forecast period 2022-2029. The expected CAGR of global marginal zone lymphoma treatment market. is tend to be around 6% in the mentioned forecast period. The market was valued at USD 508.6 billion in 2021, and it would grow upto USD 810.63 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Marginal zone lymphoma is a subtype of B-cell non-Hodgkin lymphoma (NHL) of heterogeneous group of lymphomas. In this lymphoma, the cancer originates from post-germinal marginal zone B cells in the lymph nodes. The typical symptoms include extreme tiredness, abdominal pain, skin rash, and weight loss among others. Marginal zone lymphoma mostly results in the abnormal formation of B-lymphocytes in the lymph nodes. B-lymphocytes are a kind of white blood cells and major constituents of the human immune system. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Marginal Zone Lymphoma Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Immunotherapy, Radiation Therapy, Chemotherapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.)
|
|
Market Opportunities
|
|
Global Marginal Zone Lymphoma Treatment Market Dynamics
Drivers
- Increase in Geriatric Population
The geriatric population is expected to increase the patient population globally, which boots the market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. The possibility of getting infected with varied types of cancer also rises. This boost the market growth.
- Development in Drug Production
There has been increased approvals and development of drugs that are helpful in treating patients suffering from marginal zone lymphoma. For instance, in May 2019, the FDA approved lenalidomide (Revlimid) along with a rituximab product for previously treated follicular lymphoma (FL) and previously-treated MZL. Revlimid is an immune-modulating therapy that has proven anti-myeloma e?ects. This is an oral therapy that was shown to work in 3 ways in animal models and in vitro, it helps the immune system to identify and eliminate myeloma cells. Thus, this factor boost the market growth.
Opportunities
- Surge in usage in Hospitals
Hospitals and specialty clinics are the biggest consumer of the any type of lymphoma treatment market and it is rising because of the development of more and more hospitals. In addition to this, healthcare companies are also launching new and improved formulations of drugs for lowering the lymphoma cases.
- Rising Healthcare Awareness
Health awareness amongst the population are increasing, leading to the huge production of drugs boost the market growth. The innovative launches in medications for the treatment of marginal zone lymphoma are expected to prompt the market simultaneously. Different researchers are investing in launching the drugs that benefit the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the knowledge of the treatment process could curb the growth of the global marginal zone lymphoma treatment market. over a forecast period.
- Side Effects of Marginal Zone Lymphoma Treatment
There are various side effects that may hinder the growth of the market. Adverse effects such as anemia, hair loss, fatigue, and nausea cause the patient’s life difficulties. The diseased condition is severe and thus many of the patients require chemotherapy which can lead to side-effects such as sore mouth, loss of appetite, tiredness, infections and many such factors.
This global marginal zone lymphoma treatment market. report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global marginal zone lymphoma treatment market. contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Marginal Zone Lymphoma Treatment Market Scope
The global marginal zone lymphoma treatment market. is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Radiation Therapy
- Involved field
- Involved site
- Immunotherapy
- Rituximab
- Chemotherapy
- Cyclophosphamide
- Doxorubicin
- Vincristine
- Prednisone
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Marginal Zone Lymphoma Treatment Market Regional Analysis/Insights
The global marginal zone lymphoma treatment market.is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global marginal zone lymphoma treatment market.report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth to the increase prevalence of marginal zone lymphoma and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Marginal Zone Lymphoma Treatment Market Share Analysis
The global marginal zone lymphoma treatment market.competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global marginal zone lymphoma treatment market.
Key players operating in the global marginal zone lymphoma treatment market.include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
SKU-